Targeting neoantigens for cancer immunotherapy
Authors:
Open Access
- 28 July 2021
- journal article
- review article
- Published by Springer Nature in Biomarker Research
- Vol. 9 (1) , 1-12
Abstract
Neoantigens, a type of tumor-specific antigens derived from non-synonymous mutations, have recently been characterized as attractive targets for cancer immunotherapy. Owing to the development of next-generation sequencing and utilization of machine-learning algorithms, it has become feasible to computationally predict neoantigens by depicting genetic alterations, aberrant post-transcriptional mRNA processing and abnormal mRNA translation events within tumor tissues. Consequently, neoantigen-based therapies such as cancer vaccines have been widely tested in clinical trials and have demonstrated promising safety and efficacy, opening a new era for cancer immunotherapy. We systematically summarize recent advances in the identification of both personalized and public neoantigens, neoantigen formulations and neoantigen-based clinical trials in this review. Moreover, we discuss future techniques and strategies for neoantigen-based cancer treatment either as a monotherapy or as a combination therapy with radiotherapy, chemotherapy or immune checkpoint inhibitors.Keywords
Funding Information
- National Natural Science Foundation of China (81802857)
- the national key Research and Development Program of China (2018YFC1313400)
- National Science and Technology Major Project of China (2020ZX09201-009)
This publication has 71 references indexed in Scilit:
- Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015The Lancet, 2016
- The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic ApproachesAnnual Review of Biochemistry, 2016
- A second chance for telomerase reverse transcriptase in anticancer immunotherapyNature Reviews Clinical Oncology, 2016
- Immune evasion in cancer: Mechanistic basis and therapeutic strategiesSeminars in Cancer Biology, 2015
- A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with ResponseClinical Cancer Research, 2015
- Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapyNature Reviews Cancer, 2014
- Cancer testis antigen and immunotherapyImmunoTargets and Therapy, 2013
- Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate CancerJournal of Clinical Oncology, 2006
- Combination immunotherapy with prostatic acid phosphatase pulsed antigen‐presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapyCancer, 2006
- Immunity to Melanoma Antigens: From Self‐Tolerance to Immunotherapy2006